Progress in diagnostic methods and vaccines for lumpy skin disease virus: a path towards understanding the disease

Lumpy skin disease (LSD) is caused by Lumpy Skin disease virus (LSDV) belonging to the genus Capripoxvirus (CaPV). The disease is widespread in Africa, the Middle East and Asia and has been present in Egypt since 1988. LSD is mainly transmitted by blood-sucking insects. LSD is clinically distinguished by a high fever, skin nodules, and swollen Lymph nodes. Detecting sub-clinical disease can be challenging however, prompt laboratory investigations are vital. Skin lesions are the main source of infection, although the virus is shed through many excretions and discharges including semen. Disease confirmation in clinical laboratories includes detection of viral nucleic acid, antigen and antibody levels. Simple, adaptable, and quick assays for detecting LSDV are required for control measures. Vaccination, together with controlled quarantine and vector control measures, may be beneficial for preventing disease spread. Presently, a range of live attenuated vaccines, have been used in the field with different levels of protection and side effects. With high levels of vaccination coverage, attenuated Neethling vaccines have successfully eradicated of LSDV in Europe. Inactivated LSDV vaccines have also been demonstrated effective in experimental infections. Furthermore, due to its large genome, LSDV is being exploited as a vaccine delivery element, generating an innovative composite with additional viral genes by DNA recombination. Vaccines developed on this basis have the potential to prevent a wide range of diseases and have been demonstrated to be effective in experimental settings. In this review, we emphasizethe advances in diagnostic methods and vaccines developed last decade, thereby providing a basis for future research into various aspects of LSDV and providing information for possibility of disease elimination.